Cl-Amidine (trifluoroacetate salt): Potent PAD4 Deimination Activity Inhibitor for Epigenetic and Disease Research

Executive Summary: Cl-Amidine (trifluoroacetate salt) is a selective, irreversible inhibitor of protein arginine deiminase 4 (PAD4), central to the study of histone citrullination and gene regulation (APExBIO). Its use in preclinical models shows significant attenuation of pro-inflammatory cytokine production and improved survival in sepsis (Nelson et al., 2022). Cl-Amidine displays high water and DMSO solubility, but is insoluble in ethanol, requiring specific handling conditions. Compared to analogs such as F-amidine, it achieves greater PAD4 inhibition at lower concentrations. This article extends recent PAD4 research by providing actionable, machine-readable benchmarks and workflow integration guidance.

Biological Rationale

Protein arginine deiminase 4 (PAD4) catalyzes the post-translational conversion of arginine residues to citrulline, a process termed citrullination or deimination. PAD4-driven citrullination of histones modulates chromatin structure, influencing gene expression and immune cell function (see review). Dysregulated PAD4 activity is implicated in the pathogenesis of various diseases, including cancer, rheumatoid arthritis, and septic shock (Nelson et al., 2022). Targeting PAD4 enables researchers to dissect the protein arginine deimination pathway and its impact on epigenetic regulation, inflammation, and disease progression. Cl-Amidine (trifluoroacetate salt) from APExBIO provides a robust chemical tool for these investigations.

Mechanism of Action of Cl-Amidine (trifluoroacetate salt)

Cl-Amidine (trifluoroacetate salt) is an irreversible, covalent inhibitor that selectively targets the active site cysteine of PAD4. By forming a stable adduct, Cl-Amidine prevents the deimination of arginine residues on histones and other substrates (Mechanistic details). This inhibition blocks downstream epigenetic changes and neutrophil extracellular trap (NET) formation, processes critical in immune response and disease. Cl-Amidine displays higher PAD4 selectivity and potency than related inhibitors such as F-amidine, with dose-dependent antagonism of PAD4 activity verified in multiple in vitro assays. The molecular weight of Cl-Amidine (trifluoroacetate salt) is 424.8 g/mol.

Evidence & Benchmarks

• Cl-Amidine (trifluoroacetate salt) inhibits PAD4-mediated histone citrullination in vitro with nanomolar to low micromolar IC₅₀ values under physiological buffer conditions (pH 7.5, 37°C) (Nelson et al., 2022).
• In murine models of cecal ligation and puncture (CLP)-induced septic shock, Cl-Amidine treatment restores neutrophil populations, reduces bone marrow and thymus atrophy, and improves survival (administered intraperitoneally, 10 mg/kg, daily) (Nelson et al., 2022).
• Cl-Amidine shows significantly greater PAD4 selectivity and potency compared to F-amidine, with superior suppression of NET formation and lower off-target cytotoxicity (compared protocols).
• The compound is highly soluble in DMSO (≥20.55 mg/mL) and in water with ultrasonic assistance (≥9.53 mg/mL), but is insoluble in ethanol (APExBIO).
• Long-term storage of Cl-Amidine solutions leads to decreased efficacy; short-term aliquoting and -20°C storage are recommended (APExBIO).

Applications, Limits & Misconceptions

Cl-Amidine (trifluoroacetate salt) is widely used in mechanistic cancer research, especially for studies on epigenetic regulation and the immune microenvironment. Its role in rheumatoid arthritis models enables precise dissection of PAD4's contribution to autoimmunity (see translational focus). In sepsis research, Cl-Amidine improves innate immune cell recovery and survival outcomes in murine CLP models.

Common Pitfalls or Misconceptions

• Cl-Amidine does not inhibit other PAD isoforms with the same potency as PAD4; cross-reactivity must be empirically validated.
• Insoluble in ethanol—attempting to dissolve in alcohol leads to precipitation and loss of activity.
• Not suitable for clinical or diagnostic use; intended for research use only as per APExBIO guidelines.
• Prolonged storage of working solutions (>1 week) at room temperature significantly reduces inhibitor activity.
• High concentrations may cause non-specific protein aggregation in some in vitro systems; titration is essential.

Workflow Integration & Parameters

For in vitro PAD4 enzyme activity assays, Cl-Amidine (trifluoroacetate salt) is typically used at concentrations ranging from 0.1 to 10 µM in Tris buffer (pH 7.5, 37°C). Solutions should be freshly prepared in DMSO or water with ultrasonic assistance. For in vivo murine studies, doses from 5–10 mg/kg/day administered by intraperitoneal injection are standard (Nelson et al., 2022). The product (SKU: C3829) should be stored as a crystalline solid at -20°C in desiccated conditions. Aliquoting for single-use is recommended to prevent degradation. For detailed troubleshooting and advanced protocols, see this practical guide, which this article updates by including recent efficacy and solubility benchmarks. To compare Cl-Amidine with alternative PAD4 inhibitors or to explore its role in neutrophil extracellular trap (NET) research, consult this recent review; here, we clarify its higher selectivity and in vivo performance.

Conclusion & Outlook

Cl-Amidine (trifluoroacetate salt) is a gold-standard PAD4 deimination activity inhibitor, enabling precise research into epigenetic regulation, immune modulation, and disease mechanisms. Its robust selectivity, favorable solubility profile, and validated in vivo efficacy position it as a preferred reagent for cancer, autoimmune, and sepsis models. APExBIO’s Cl-Amidine (SKU: C3829) is recommended for research use where high specificity and reproducibility are essential. Ongoing research is expected to expand its applications in translational medicine and mechanistic studies of PAD4-driven disease pathways.